XL 1p36/1q25 del consists of an orange-labeled probe hybridizing to the CHD5 gene region at 1p36.3 and a green-labeled probe hybridizing to the ABL2 gene region at 1q25.2.

Probe maps for selected products have been updated. These updates ensure a consistent presentation of all gaps larger than 10 kb including adjustments to markers, genes, and related elements. This update does not affect the device characteristics or product composition. Please refer to the list to find out which products now include updated probe maps.

Probe map details are based on UCSC Genome Browser GRCh37/hg19, with map components not to scale.

The 2016 ´World Health Organization Classification of Tumors of the Central Nervous System´ (WHO 2016) combines, for the first time, histological features and molecular signatures for the definition of many tumor entities. Gliomas are a category of tumors of the brain and spinal cord starting in glia cells. Oligodendrogliomas are a subtype of gliomas accounting for up to 18% of all cases. According to the WHO 2016, the classification of an oligodendroglioma requires information about the isocitrate dehydrogenase mutation status and 1p/19q loss of heterozygosity (LOH). LOH of 1p can be detected in about 67% of oligodendroglial tumors and has also been identified in neuroblastomas and other tumor entities. Co-deletion of 1p/19q is a well-accepted prognostic biomarker in neuro-oncology. Patients suffering from anaplastic oligodendroglioma harboring 1p/19q deletion generally have a good prognosis. Co-deletion of 1p/19q also has predictive character, the molecular status of 1p/19q is relevant for therapy decisions.

Clinical Applications

• Solid Tumors (Solid Tumors)

XL 1p36/1q25 del hybridized to lymphocytes. One normal interphase and one partial metaphase are shown.

• Reifenberger et al (1994) Am J Pathol 145:1175-1190
• Louis et al (2016) Acta Neuropathol 131:803-820
• Staedtke et al (2016) Trends Cancer 2:338-349